Current treatments

Update of the GEM2005 trial comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Mateos MV et al. Blood. 2014 Aug 7. pii: blood-2014-05-573733. [Epub ahead of print]. Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood…

Details

Guidelines for the diagnosis and management of multiple myeloma 2013 – presentation and diagnosis

These updated guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the diagnosis and management of myeloma patients. They should be read in conjunction with the BCSH Guidelines on the supportive care of myeloma patients. Bird et al.…

Details

Guidelines for supportive care in multiple myeloma 2011

These guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the supportive care of myeloma patients and should be read in conjunction with the BCSH Guidelines for the diagnosis and management of myeloma.

IMWG Guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

This paper provides an update to the first guideline published in 2005 by the International Myeloma Working Group on the management of myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation. It includes recommendations on the diagnosis and treatment of these patients together with the management of side-effects of treatment.

IMWG Recommendations for the treatment of multiple myeloma-related bone disease

This paper, written by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the available evidence and provides recommendations for the management of myeloma-related bone disease. It also includes expert consensus to propose additional recommendations where there were insufficient published data.

UKMF Guidelines on the diagnosis and management of solitary plasmacytomas: 2009 update

This paper provides updated guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas and incorporates further available information on diagnosis, prognosis and management and a new section on the management of multiple solitary plasmacytomas.

Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance

These guidelines, written by the UK Myeloma Forum in conjunction with the Nordic Myeloma Study Group provide guidance for the effective clinical investigation of patients with newly detected paraprotein and the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS).